- Home
- ITRM vs PRME Comparison
ITRM vs PRME Comparison
Compare ITRM & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITRM | PRME |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 666.1M |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ITRM | PRME |
|---|---|---|
| Price | $0.03 | $3.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $9.00 | $7.56 |
| AVG Volume (30 Days) | ★ 22.8M | 2.3M |
| Earning Date | 05-12-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.43 | 18.18 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,632,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $947.65 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $0.03 | $1.11 |
| 52 Week High | $1.42 | $6.94 |
Technical Indicators
Market Signals| Indicator | ITRM | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 26.10 | 44.74 |
| Support Level | N/A | $3.19 |
| Resistance Level | $0.39 | $4.74 |
| Average True Range (ATR) | 0.02 | 0.24 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 3.34 | 53.46 |
Price Performance
Historical ComparisonAbout ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.